Related Experiment Videos
Immunosuppressive therapy in rheumatoid arthritis
1Medizinischen Universitätsklinik Graz.
Acta Medica Austriaca
|January 1, 1988
Summary
Immunosuppressive drugs effectively treat rheumatoid arthritis but carry significant side effects and potential cancer risks. Their use is reserved for severe cases unresponsive to less toxic treatments, with guidelines provided for careful application.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Immunosuppressive drugs have been utilized for rheumatoid arthritis treatment since 1951.
- Key drugs include azathioprine, cyclophosphamide, chlorambucil, and methotrexate.
- The clinical efficacy of these agents is well-established.
Purpose of the Study:
- To discuss the efficacy and side effects of immunosuppressive drugs in rheumatoid arthritis.
- To provide guidelines for the appropriate use of these potent medications.
- To address the uncertainties surrounding the long-term cancerogenicity of immunosuppressive therapy.
Main Methods:
- Literature review and synthesis of existing clinical data.
- Discussion of established immunosuppressive agents used in rheumatology.
- Analysis of reported efficacy and adverse event profiles.
Main Results:
- Immunosuppressive drugs demonstrate clinical efficacy in rheumatoid arthritis management.
- These medications are associated with a higher incidence of severe side effects.
- The long-term cancerogenic potential remains unclear and requires further investigation.
Conclusions:
- Immunosuppressive therapy should be reserved for severe rheumatoid arthritis cases refractory to less toxic treatments.
- Careful consideration of the risk-benefit profile is essential due to significant side effects and unclear cancer risks.
- Guidelines are provided to aid clinicians in the judicious use of immunosuppressive drugs for rheumatoid arthritis.